Dapsone - USA

IPR decision: Aug. 27, 2019

AIA Review	Filing Date	Institution Date	Petitioner	US Patent	Respondent	Final Decision
IPR2018-00608	02/12/2018	08/29/2018	Amneal Pharma. LLC	9,161,926	Allergan, Inc.	Claims 1–6 are patentable

US 9,161,926 (Allergan, Inc.; Exp: 11/18/2033) – listed in OB

1. A topical pharmaceutical composition comprising: about 7.5% w/w dapsone; about 30% w/w to about 40% w/w diethylene glycol monoethyl ether; about 2% w/w to about 6% w/w of a polymeric viscosity builder consisting of acrylamide/sodium acryloyldimethyl taurate copolymer; and water; wherein the composition does not comprise adapalene.

5. A topical pharmaceutical composition comprising: about 7.5% w/w dapsone; about 30% w/w diethylene glycol monoethyl ether; about 4% w/w of a polymeric viscosity builder consisting of acrylamide/sodium acryloyldimethyl taurate copolymer; and water; wherein the composition does not comprise adapalene.